Prophylactic paclitaxel-eluting stent placement does not improve covered femoropopliteal stent patency

Objective: Covered stents are an important tool in managing femoropopliteal peripheral arterial disease. However, their performance is impaired by edge neointimal hyperplasia and restenosis. We examined the effectiveness of prophylactic deployment of paclitaxel-eluting stents to prevent edge resteno...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Rory Marples, MBBS, Matthew Binks, MBBS, Roberto Spina, MBBS, MSc, MPH, FRACP, Melissa Wright, MD, Ravi Huilgol, MBBS, FRACS
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2022
Materias:	Surgery RD1-811
Acceso en línea:	https://doaj.org/article/151040d0d3a44a95b7e70b56e61a2849
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:151040d0d3a44a95b7e70b56e61a2849
record_format	dspace
spelling	oai:doaj.org-article:151040d0d3a44a95b7e70b56e61a28492021-11-10T04:40:10ZProphylactic paclitaxel-eluting stent placement does not improve covered femoropopliteal stent patency2589-845010.1016/j.sopen.2021.09.004https://doaj.org/article/151040d0d3a44a95b7e70b56e61a28492022-01-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S258984502100021Xhttps://doaj.org/toc/2589-8450Objective: Covered stents are an important tool in managing femoropopliteal peripheral arterial disease. However, their performance is impaired by edge neointimal hyperplasia and restenosis. We examined the effectiveness of prophylactic deployment of paclitaxel-eluting stents to prevent edge restenosis. Methods: A retrospective case–control study was performed. Patients with femoropopliteal peripheral arterial disease who were treated with Viabahn stent placement were compared to patients treated with Viabahn stents deployed in conjunction with paclitaxel-eluting stents (PTX). The primary outcome was time to loss of stent primary patency. The Kaplan–Meier method was used. Results: A total of 36 Viabahn and 25 Viabahn + paclitaxel-eluting stent procedures were evaluated, with mean follow-up periods of 27 and 18 months, respectively. The Viabahn + paclitaxel-eluting stent group had a longer length of vessel stented (P = .0023). Twelve-month primary patency was 74% in the Viabahn group and 75% in the Viabahn + paclitaxel-eluting stent group. Pre-existing dyslipidemia correlated with earlier loss of primary patency across the combined cohort (P = .0193). Conclusion: Viabahn stent primary patency is unaffected by the addition of paclitaxel-eluting stents.Rory Marples, MBBSMatthew Binks, MBBSRoberto Spina, MBBS, MSc, MPH, FRACPMelissa Wright, MDRavi Huilgol, MBBS, FRACSElsevierarticleSurgeryRD1-811ENSurgery Open Science, Vol 7, Iss , Pp 18-21 (2022)
institution	DOAJ
collection	DOAJ
language	EN
topic	Surgery RD1-811
spellingShingle	Surgery RD1-811 Rory Marples, MBBS Matthew Binks, MBBS Roberto Spina, MBBS, MSc, MPH, FRACP Melissa Wright, MD Ravi Huilgol, MBBS, FRACS Prophylactic paclitaxel-eluting stent placement does not improve covered femoropopliteal stent patency
description	Objective: Covered stents are an important tool in managing femoropopliteal peripheral arterial disease. However, their performance is impaired by edge neointimal hyperplasia and restenosis. We examined the effectiveness of prophylactic deployment of paclitaxel-eluting stents to prevent edge restenosis. Methods: A retrospective case–control study was performed. Patients with femoropopliteal peripheral arterial disease who were treated with Viabahn stent placement were compared to patients treated with Viabahn stents deployed in conjunction with paclitaxel-eluting stents (PTX). The primary outcome was time to loss of stent primary patency. The Kaplan–Meier method was used. Results: A total of 36 Viabahn and 25 Viabahn + paclitaxel-eluting stent procedures were evaluated, with mean follow-up periods of 27 and 18 months, respectively. The Viabahn + paclitaxel-eluting stent group had a longer length of vessel stented (P = .0023). Twelve-month primary patency was 74% in the Viabahn group and 75% in the Viabahn + paclitaxel-eluting stent group. Pre-existing dyslipidemia correlated with earlier loss of primary patency across the combined cohort (P = .0193). Conclusion: Viabahn stent primary patency is unaffected by the addition of paclitaxel-eluting stents.
format	article
author	Rory Marples, MBBS Matthew Binks, MBBS Roberto Spina, MBBS, MSc, MPH, FRACP Melissa Wright, MD Ravi Huilgol, MBBS, FRACS
author_facet	Rory Marples, MBBS Matthew Binks, MBBS Roberto Spina, MBBS, MSc, MPH, FRACP Melissa Wright, MD Ravi Huilgol, MBBS, FRACS
author_sort	Rory Marples, MBBS
title	Prophylactic paclitaxel-eluting stent placement does not improve covered femoropopliteal stent patency
title_short	Prophylactic paclitaxel-eluting stent placement does not improve covered femoropopliteal stent patency
title_full	Prophylactic paclitaxel-eluting stent placement does not improve covered femoropopliteal stent patency
title_fullStr	Prophylactic paclitaxel-eluting stent placement does not improve covered femoropopliteal stent patency
title_full_unstemmed	Prophylactic paclitaxel-eluting stent placement does not improve covered femoropopliteal stent patency
title_sort	prophylactic paclitaxel-eluting stent placement does not improve covered femoropopliteal stent patency
publisher	Elsevier
publishDate	2022
url	https://doaj.org/article/151040d0d3a44a95b7e70b56e61a2849
work_keys_str_mv	AT rorymarplesmbbs prophylacticpaclitaxelelutingstentplacementdoesnotimprovecoveredfemoropoplitealstentpatency AT matthewbinksmbbs prophylacticpaclitaxelelutingstentplacementdoesnotimprovecoveredfemoropoplitealstentpatency AT robertospinambbsmscmphfracp prophylacticpaclitaxelelutingstentplacementdoesnotimprovecoveredfemoropoplitealstentpatency AT melissawrightmd prophylacticpaclitaxelelutingstentplacementdoesnotimprovecoveredfemoropoplitealstentpatency AT ravihuilgolmbbsfracs prophylacticpaclitaxelelutingstentplacementdoesnotimprovecoveredfemoropoplitealstentpatency
_version_	1718440532751941632

Prophylactic paclitaxel-eluting stent placement does not improve covered femoropopliteal stent patency

Ejemplares similares